感染指南

订阅

MedSci主页 / 所有栏目 / 感染指南

2015 CPIC指南： UGT1A1和阿扎那韦处方

2015-11-09 临床药物基因组学实施联盟 Clin Pharmacol Ther. 2016 Apr;99(4):363-9.

阿扎那韦

2015年11月，临床药物基因组学实施联盟(CPIC)发布了 UGT1A1和阿扎那韦处方指南，目的是为临床UGT1A1基因测试提供信息，从而指导阿扎那韦处方用药。

中文标题：

2015 CPIC指南： UGT1A1和阿扎那韦处方

英文标题：

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

发布机构：

临床药物基因组学实施联盟

发布日期：

2015-11-09

简要介绍：

2015年11月，临床药物基因组学实施联盟(CPIC)发布了UGT1A1和阿扎那韦处方指南，目的是为临床UGT1A1基因测试提供信息，从而指导阿扎那韦处方用药。

拓展指南：与阿扎那韦相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2015 CPIC指南： UGT1A1和阿扎那韦处方)] GetToolGuiderByIdResponse(projectId=1, id=af4a31c00125a695, title=2015 CPIC指南： UGT1A1和阿扎那韦处方, enTitle=Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing., guiderFrom=Clin Pharmacol Ther. 2016 Apr;99(4):363-9., authorId=null, author=, summary=2015年11月，临床药物基因组学实施联盟(CPIC)发布了 UGT1A1和阿扎那韦处方指南，目的是为临床UGT1A1基因测试提供信息，从而指导阿扎那韦处方用药。, cover=, journalId=null, articlesId=null, associationId=1236, associationName=临床药物基因组学实施联盟, associationIntro=, copyright=0, guiderPublishedTime=Mon Nov 09 00:00:00 CST 2015, originalUrl=, linkOutUrl=, content=2015年11月，临床药物基因组学实施联盟(CPIC)发布了UGT1A1和阿扎那韦处方指南，目的是为临床UGT1A1基因测试提供信息，从而指导阿扎那韦处方用药。<br> <br>拓展指南：<strong>与<font color="red">阿扎那韦</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=af4a31c00125a695" title="2015 CPIC指南： UGT1A1和阿扎那韦处方" target="_blank">2015 CPIC指南： UGT1A1和阿扎那韦处方</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E9%98%BF%E6%89%8E%E9%82%A3%E9%9F%A6" target="_blank">有关阿扎那韦更多指南</a></ul>, tagList=[TagDto(tagId=18173, tagName=阿扎那韦)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3774, appHits=28, showAppHits=0, pcHits=2896, showPcHits=1232, likes=147, shares=0, comments=2, approvalStatus=1, publishedTime=Tue Aug 16 10:03:39 CST 2016, publishedTimeString=2015-11-09, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Tue Aug 16 10:03:39 CST 2016, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 19:20:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2015 CPIC指南： UGT1A1和阿扎那韦处方)])
2015 CPIC指南： UGT1A1和阿扎那韦处方
下载请点击：
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=99857, encodeId=e8c19985e1f, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:33:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99858, encodeId=3f559985890, content=继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:33:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2016-08-17 doctorJiangchao

    继续学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=99857, encodeId=e8c19985e1f, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:33:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=99858, encodeId=3f559985890, content=继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Aug 17 17:33:00 CST 2016, time=2016-08-17, status=1, ipAttribution=)]
    2016-08-17 doctorJiangchao

    继续关注

    0